Atypical Neuroleptics

Citations 1-10 of 313 total displayed.

Most recent content (1 Aug 2008):

Editorials
Cholinergic Agonists as Novel Treatments for Schizophrenia: The Promise of Rational Drug Development for Psychiatry

Jeffrey A. Lieberman, Jonathan A. Javitch, and Holly Moore
Am J Psychiatry 2008; 165: 931-936. [Full text] [PDF]  

Editorials
New Insights Into Clinical Response in Schizophrenia: From Dopamine D₂ Receptor Occupancy to Patients’ Quality of Life

Donald C. Goff
Am J Psychiatry 2008; 165: 940-943. [Full text] [PDF]  

Clinical Case Conference
Schizophrenia in a Patient With Spinocerebellar Ataxia 2: Coincidence of Two Disorders or a Neurodegenerative Disease Presenting With Psychosis?

Matthew Rottnek, Silvana Riggio, William Byne, Mary Sano, Russell L. Margolis, and Ruth H. Walker
Am J Psychiatry 2008; 165: 964-967. [Full text] [PDF]  

Articles
Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [¹⁸F]Fallypride PET Study

Gerhard Gründer, Christine Fellows, Hildegard Janouschek, Tanja Veselinovic, Christian Boy, Anno Bröcheler, Katrin M. Kirschbaum, Sandra Hellmann, Katja M. Spreckelmeyer, Christoph Hiemke, Frank Rösch, Wolfgang M. Schaefer, and Ingo Vernaleken
Am J Psychiatry 2008; 165: 988-995. [Abstract] [Full text] [PDF]  

Articles
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Anantha Shekhar, William Z. Potter, Jeffrey Lightfoot, John Lienemann, Sanjay Dubé, Craig Mallinckrodt, Frank P. Bymaster, David L. McKinzie, and Christian C. Felder
Am J Psychiatry 2008; 165: 1033-1039. [Abstract] [Full text] [PDF]  

Articles
Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

Robert Freedman, Ann Olincy, Robert W. Buchanan, Josette G. Harris, James M. Gold, Lynn Johnson, Diana Allensworth, Alejandrina Guzman-Bonilla, Bettye Clement, M. Patricia Ball, Jay Kutnick, Vicki Pender, Laura F. Martin, Karen E. Stevens, Brandie D. Wagner, Gary O. Zerbe, Ferenc Soti, and William R. Kem
Am J Psychiatry 2008; 165: 1040-1047. [Abstract] [Full text] [PDF]  

Past content (since Jun 2002):

Editorials
Atypical Antipsychotic Medications in Alzheimer’s Disease: Effectiveness Versus Expectations

Susan K. Schultz
Am J Psychiatry 2008; 165: 787-789. [Full text] [PDF]  

Clinical Case Conference
Rechallenging With Clozapine Following Neutropenia: Treatment Options for Refractory Schizophrenia

Sharmin Ghaznavi, Marina Nakic, Paul Rao, Jian Hu, Judson A. Brewer, Jonas Hannestad, and Zubin Bhagwagar
Am J Psychiatry 2008; 165: 813-818. [Full text] [PDF]  

Articles
Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial

David L. Sultzer, Sonia M. Davis, Pierre N. Tariot, Karen S. Dagerman, Barry D. Lebowitz, Constantine G. Lyketsos, Robert A. Rosenheck, John K. Hsiao, Jeffrey A. Lieberman, Lon S. Schneider, and CATIE-AD Study Group
Am J Psychiatry 2008; 165: 844-854. [Abstract] [Full text] [PDF]  

Reviews and Overviews
Medication Effects in Neuroimaging Studies of Bipolar Disorder

Mary L. Phillips, Michael J. Travis, Andrea Fagiolini, and David J. Kupfer
Am J Psychiatry 2008; 165: 313-320. [Abstract] [Full text] [PDF]  

[Next page] Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32